IRIS UniCatt

D'Amico, Adele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.484
EU - Europa 3.263
AS - Asia 2.653
SA - Sud America 509
AF - Africa 72
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 4
Totale 9.995
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.361
SG - Singapore 1.280
DE - Germania 1.111
CN - Cina 583
IT - Italia 404
BR - Brasile 401
NL - Olanda 380
SE - Svezia 369
FR - Francia 245
VN - Vietnam 203
IE - Irlanda 180
GB - Regno Unito 148
IN - India 117
UA - Ucraina 110
JP - Giappone 86
ID - Indonesia 82
FI - Finlandia 72
RU - Federazione Russa 59
CA - Canada 58
HK - Hong Kong 55
AR - Argentina 49
BD - Bangladesh 47
PL - Polonia 45
TR - Turchia 34
MX - Messico 33
ES - Italia 28
IQ - Iraq 28
KR - Corea 23
ZA - Sudafrica 21
BE - Belgio 19
AT - Austria 17
EC - Ecuador 17
PK - Pakistan 17
IR - Iran 15
CH - Svizzera 14
CO - Colombia 13
MA - Marocco 13
CZ - Repubblica Ceca 12
VE - Venezuela 11
PA - Panama 10
UZ - Uzbekistan 10
LT - Lituania 9
EG - Egitto 8
IL - Israele 8
CI - Costa d'Avorio 7
SA - Arabia Saudita 7
AU - Australia 6
KE - Kenya 6
NP - Nepal 6
PE - Perù 6
PH - Filippine 6
TN - Tunisia 6
CL - Cile 5
CR - Costa Rica 5
MY - Malesia 5
PY - Paraguay 5
RO - Romania 5
AL - Albania 4
AM - Armenia 4
DK - Danimarca 4
DZ - Algeria 4
JM - Giamaica 4
KG - Kirghizistan 4
KZ - Kazakistan 4
OM - Oman 4
SK - Slovacchia (Repubblica Slovacca) 4
TT - Trinidad e Tobago 4
AE - Emirati Arabi Uniti 3
GR - Grecia 3
HU - Ungheria 3
LB - Libano 3
LV - Lettonia 3
ME - Montenegro 3
NG - Nigeria 3
NZ - Nuova Zelanda 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BN - Brunei Darussalam 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
LK - Sri Lanka 2
LY - Libia 2
NI - Nicaragua 2
PT - Portogallo 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BY - Bielorussia 1
DM - Dominica 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
JO - Giordania 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 9.985
Salva come PNG Salva come JPEG
Città #
Singapore 747
Ashburn 406
Chandler 392
San Jose 361
Amsterdam 350
New York 170
Dublin 166
Frankfurt am Main 144
Beijing 113
Los Angeles 92
Rome 92
Tokyo 78
Jakarta 75
Lauterbourg 74
San Mateo 72
Hefei 70
Milan 67
Ho Chi Minh City 62
Jacksonville 61
Houston 59
Hanoi 58
Boston 55
Dallas 53
Hong Kong 52
Munich 50
Wilmington 50
Chicago 46
Moscow 43
Nanjing 43
São Paulo 41
Nürnberg 40
Marseille 38
Santa Clara 37
Helsinki 32
Bremen 30
Princeton 30
Buffalo 29
Warsaw 29
Woodbridge 29
Ann Arbor 28
Dearborn 27
Tukwila 27
Orem 24
The Dalles 24
Boardman 23
Lawrence 23
London 23
Brooklyn 22
Seoul 22
Chennai 21
Denver 20
Nuremberg 19
Paris 19
Seattle 19
Fairfield 18
Kent 17
San Francisco 17
Atlanta 16
Johannesburg 16
Lancaster 16
Montreal 16
Rio de Janeiro 16
Changsha 15
Council Bluffs 15
Hebei 15
Izmir 15
Nanchang 15
Poplar 15
Redwood City 15
Toronto 15
Brussels 13
Cattolica 13
Inverigo 13
Buenos Aires 12
Da Nang 12
Guangzhou 12
Mexico City 12
Phoenix 12
Stockholm 12
Washington 12
Baghdad 11
Tianjin 11
Augusta 10
Düsseldorf 10
Norwalk 10
Shanghai 10
Turku 10
Charlotte 9
Columbus 9
Detroit 9
Leawood 9
Manchester 9
Pune 9
Zhengzhou 9
Belo Horizonte 8
Cambridge 8
Hangzhou 8
Kish 8
Naples 8
Palermo 8
Totale 5.335
Salva come PNG Salva come JPEG
Nome #
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 681
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 503
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 311
Spinal muscular atrophy 248
Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. 181
SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. 179
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 179
Broad phenotypic spectrum and genotype-phenotype correlations in GMPPB-related dystroglycanopathies: an Italian cross-sectional study. 176
Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study 165
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 165
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 164
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 161
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 156
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standars of Care? 155
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience 153
Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy 149
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 148
Clinical-genetic features and peculiar muscle histopathology in infantile DNM1L-related mitochondrial epileptic encephalopathy 144
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 143
2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants 142
Expanding the clinical-pathological and genetic spectrum of RYR1-related congenital myopathies with cores and minicores: an Italian population study 138
24 month longitudinal data in ambulant boys with duchenne muscular dystrophy 137
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 134
Genetic characterization in symptomatic female DMD carriers: lack of relationship between X-inactivation, transcriptional DMD allele balancing and phenotype 134
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 133
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 132
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 131
Prevalence of Duchenne muscular dystrophy in Italy: a nationwide survey 130
Outcome of fetuses with congenital cytomegalovirus infection: a systematic review and meta-analysis 130
Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study 130
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 128
Role of prenatal magnetic resonance imaging in fetuses with isolated anomalies of corpus callosum: multinational study 124
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 124
The empowerment of translational research: lessons from laminopathies 124
Genetic modifiers of upper limb function in Duchenne muscular dystrophy 121
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 121
Copy Number Variants Account for a Tiny Fraction of Undiagnosed Myopathic Patients. 119
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 118
An Italian family with autosomal recessive inclusion-body myopathy and mutations in the GNE gene 116
Fetal acetylcholine receptor inactivation syndrome and maternal myasthenia gravis: a case report 115
Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study 115
Histological effects of givinostat in boys with Duchenne muscular dystrophy 114
Clinical Variability in Spinal Muscular Atrophy Type III. 114
Longitudinal natural history in young boys with Duchenne muscular dystrophy 113
Healthy design and urban planning strategies, actions, and policy to achieve salutogenic cities 112
An observational study of functional abilities in infants, children, and adults with type 1 SMA 111
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy 110
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 110
“Art, Colors, and Emotions” Treatment (ACE-t): A Pilot Study on the Efficacy of an Art-Based Intervention for People With Alzheimer’s Disease 107
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 106
Development of an academic disease registry for spinal muscular atrophy 105
MRI in sarcoglycanopathies: a large international cohort study 104
Effect of mexiletine on transitory depression of compound motor action potential in recessive myotonia congenita 102
Gain and loss of abilities in type II SMA: A 12-month natural history study 97
Registries versus tertiary care centers: How do we measure standards of care in Duchenne muscular dystrophy? 95
The genetic basis of undiagnosed muscular dystrophies and myopathies 94
New Mutations in NEB Gene Discovered by Targeted Next-Generation Sequencing in Nemaline Myopathy Italian Patients 94
Long term follow-up of scoliosis progression in type II SMA patients 93
Mosaic caveolin-3 expression in acquired rippling muscle disease without evidence of myasthenia gravis or acetylcholine receptor autoantibodies 91
MRI in sarcoglycanopathies: A large international cohort study 91
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 88
Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. 87
Early Neurodevelopmental Findings Predict School Age Cognitive Abilities in Duchenne Muscular Dystrophy: A Longitudinal Study 85
Novel Splicing Mutation in MTM1 Leading to Two Abnormal Transcripts Causes Severe Myotubular Myopathy 84
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 83
null 81
Pathogenic role of mtDNA duplications in mitochondrial diseases associated with mtDNA deletions. 81
Italian recommendations for diagnosis and management of congenital myasthenic syndromes 74
A Recurrent Pathogenic Variant of INPP5K Underlies Autosomal Recessive Congenital Muscular Dystrophy With Cataracts and Intellectual Disability: Evidence for a Founder Effect in Southern Italy 67
Muscle imaging in patients with tubular aggregate myopathy caused by mutations in STIM1 66
null 64
Mitochondrial Neurogastrointestinal Encephalomyopathy Presenting as Anorexia Nervosa 63
Developmental lag of visuospatial attention in Duchenne muscular dystrophy 56
Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation 56
Insulin-like growth factor I in inclusion-body myositis and human muscle cultures 48
Italian validation of the SMA independence scale–upper limb module 39
1st Italian SMA Family Association Consensus Meeting: Management and recommendations for respiratory involvement in spinal muscular atrophy (SMA) types I-III, Rome, Italy, 30-31 January 2015 34
1st Italian SMA Family Association Consensus Meeting: Management and recommendations for respiratory involvement in spinal muscular atrophy (SMA) types I-III, Rome, Italy, 30-31 January 2015 32
Loss of ambulation in SMA III at the time of disease-modifying treatments: an international study 10
Workshop report: Findings from the 2025 Italian SMAkers Educational Initiative on SMA management in Italy 4
Totale 10.122
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.205
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.205
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 0 0 0 0 0 2
2021/2022526 32 17 9 46 27 26 9 77 37 39 109 98
2022/20231.218 124 152 79 197 84 146 80 97 133 36 62 28
2023/2024820 39 191 43 58 39 159 51 40 22 24 67 87
2024/20251.468 36 47 111 60 139 58 77 77 187 114 299 263
2025/20264.779 526 125 250 533 795 971 677 174 223 238 180 87
Totale 10.122